Lancets Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Safety Lancets, Standard Lancets, Specialty Lancets), By Application (Glucose Testing, Haemoglobin Testing, Coagulation Testing, Other Applications), By End User (Hospitals and Clinics, Home Care Settings, Others), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.68 Billion
CAGR (2026-2031)	9.95%
Fastest Growing Segment	Safety Lancets
Largest Market	North America
Market Size (2031)	USD 4.73 Billion

Market Overview

The Global Lancets Market will grow from USD 2.68 Billion in 2025 to USD 4.73 Billion by 2031 at a 9.95% CAGR. Lancets are sterile, single-use medical devices featuring a sharp point utilized to puncture the skin for capillary blood sampling, serving as an essential tool for glucose monitoring and other diagnostic applications. The primary drivers fueling market expansion include the rising prevalence of chronic conditions requiring frequent blood testing and the increasing necessity for regular self-monitoring among patients. This demand is further supported by an aging global population and the critical requirement for infection control which mandates the use of disposable safety devices. According to the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes worldwide, creating a substantial and sustained requirement for daily monitoring supplies.

Despite this positive trajectory, the market faces impediments related to the discomfort and pain associated with repeated skin punctures, which can lead to reduced patient compliance and hinder effective disease management. Additionally, inadequate reimbursement policies for diabetes management supplies in developing regions limit accessibility and constrain broader market reach.

Key Market Drivers

The escalating global prevalence of diabetes and chronic diseases acts as the foremost catalyst for the Global Lancets Market, necessitating frequent capillary blood sampling for effective glycemic control. This surge forces a continuous demand for sterile lancing devices, particularly for home-based self-monitoring regimens which are essential for preventing long-term complications. According to the Centers for Disease Control and Prevention, May 2024, in the 'National Diabetes Statistics Report', 38.4 million people in the United States were found to have diabetes, underscoring the scale of the population requiring daily diagnostic consumables. This prevalence directly translates into sustained market value, as healthcare systems invest heavily in management supplies. According to the International Diabetes Federation, in 2024, global health expenditure on diabetes reached an estimated USD 1 trillion, highlighting the substantial economic footprint of diabetes care products, including lancets.

Concurrently, the rising adoption of safety lancets for needlestick injury prevention is restructuring the market, driven by stringent regulatory mandates and a focus on occupational safety in clinical environments. Healthcare facilities are phasing out standard devices in favor of engineered safety lancets with retractable mechanisms to mitigate accidental punctures and pathogen transmission. This transition is critical given the high burden of infectious diseases that require secure handling during diagnostic procedures. According to the World Health Organization, April 2024, in the 'Global Hepatitis Report 2024', approximately 254 million people worldwide were living with chronic hepatitis B, reinforcing the urgent necessity for safety-engineered devices to protect healthcare workers during blood screening protocols.

Download Free Sample Report

Key Market Challenges

Inadequate reimbursement policies and restricted accessibility in developing regions constitute a formidable barrier to the expansion of the global lancets market. While the clinical necessity for frequent blood glucose monitoring is well-established, the financial burden of these essential supplies often falls directly on patients in lower-income demographics where public health coverage is insufficient. This economic friction forces many individuals to ration supplies, resulting in the dangerous reuse of single-use lancets or a reduction in testing frequency, which directly suppresses the consumable sales volume that drives market revenue.

The magnitude of this economic strain is evident in the soaring costs associated with diabetes care, which places immense pressure on healthcare budgets and limits the allocation of funds for disposable diagnostics. According to the International Diabetes Federation, in 2024, diabetes was responsible for an estimated USD 1.015 trillion in global health expenditure. This colossal financial load compels payers and government bodies in resource-constrained settings to prioritize acute medication over monitoring devices, thereby stifling market penetration in high-growth potential regions. Consequently, the disparity in funding mechanisms creates a significant bottleneck, preventing the market from fully capitalizing on the rising disease prevalence in emerging economies.

Key Market Trends

The Global Lancets Market is experiencing a definitive expansion in microneedle-based blood collection technologies designed to eliminate the discomfort associated with traditional fingersticks. These innovative devices utilize microscopic arrays to draw capillary blood painlessly, directly addressing patient anxiety and improving adherence to frequent testing protocols. This technological shift is particularly impactful for decentralized clinical trials and home-based diagnostics where user experience is paramount to successful data capture. According to Tasso, Inc., March 2025, in a press statement regarding its commercial progress, the company reported having sold over 1.5 million of its patient-centric blood collection devices, validating the surging market demand for virtually pain-free sampling alternatives.

Concurrently, there is a robust industry shift toward sustainable and eco-friendly materials to mitigate the environmental footprint of single-use diagnostic consumables. Manufacturers are actively re-engineering production processes to minimize plastic waste and incorporating recycled polymers into device casings without compromising sterility or performance standards. This strategic pivot directly responds to mounting regulatory and institutional pressure to reduce the massive volume of medical waste generated by daily disposable products. According to Greiner AG, May 2025, in the 'Annual and Sustainability Report 2024', the company successfully reduced its group-wide total volume of waste by 17% in 2024, illustrating the sector-wide commitment to implementing circular economy principles within the manufacturing supply chain.

Segmental Insights

Safety lancets represent the fastest-growing segment in the global lancets market, driven primarily by strict mandates regarding healthcare worker protection. Regulatory authorities such as the Occupational Safety and Health Administration have established rigorous guidelines to minimize the risk of needlestick injuries and cross-contamination in clinical environments. This regulatory framework compels healthcare facilities to transition from standard devices to retractable safety mechanisms that prevent reuse. Furthermore, the rising prevalence of blood-borne infections accelerates the demand for single-use solutions that ensure sterility. These combined factors effectively position safety lancets as the preferred choice for capillary blood sampling in professional settings.

Regional Insights

North America dominates the Global Lancets Market primarily due to the high prevalence of diabetes which drives the demand for frequent blood glucose monitoring. The region benefits from a comprehensive healthcare infrastructure that facilitates the widespread distribution of medical supplies. Furthermore, favorable reimbursement policies in the United States significantly reduce costs for patients and encourage the adoption of home diagnostic tools. The market is also strengthened by rigorous safety standards enforced by the U.S. Food and Drug Administration. These combined factors ensure consistent demand and market stability across the region.

Recent Developments

• In September 2025, Ascensia Diabetes Care announced a strategic move to transfer the commercial operations for the Eversense Continuous Glucose Monitoring (CGM) systems to its partner, Senseonics Holdings. The companies signed a memorandum of understanding to unite the research, development, manufacturing, and commercial activities within Senseonics. Ascensia noted that the go-to-market approach for the CGM product had increasingly diverged from its core blood glucose monitoring business, which includes its portfolio of meters and lancets. This transition was intended to allow both companies to operate more efficiently and accelerate growth in their respective areas of focus within the diabetes care sector.
• In September 2024, Trividia Health expanded its product portfolio with the launch of the TRUENESS Blood Glucose Monitoring System. This new system was designed to provide advanced accuracy and cost-effectiveness for individuals managing diabetes. The launch featured the TRUENESS AIR meter, which offered Bluetooth connectivity to a dedicated mobile application, enabling users to seamlessly track their blood glucose results alongside daily activities. The company positioned this product as a high-performance solution intended to increase patient engagement and compliance through a value-driven price point available at retail pharmacies and distribution channels.
• In August 2024, Medical Technology and Devices (MTD) completed the acquisition of the pen needle and blood glucose monitoring (BGM) businesses from the Swiss company Ypsomed. This transaction, which was initially announced in March 2024, integrated Ypsomed’s operations into MTD’s European production and distribution network. The acquisition was described as a transformative milestone that solidified MTD’s position as a major player in the global diabetes care market, significantly increasing its production capacity. The deal allowed MTD to expand its portfolio of diabetes management solutions, including lancing devices and pen needles, while Ypsomed shifted its focus to insulin pump solutions.
• In March 2024, Duopharma Biotech Berhad, through its subsidiary Duopharma Marketing, entered into an exclusive distributorship agreement with a United Kingdom-based medical device manufacturer, Owen Mumford. This collaboration granted the Malaysian pharmaceutical company the rights to distribute a range of diabetes and eye care devices across Malaysia, Singapore, and Brunei. The agreement specifically included the distribution of Unistik 3 and Unilet Excelite lancets, alongside insulin pen needles. This strategic partnership aimed to supply these essential medical devices to government and private healthcare facilities as well as retail outlets, addressing the growing prevalence of diabetes in the region.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Ypsomed AG
• B. Braun SE
• Terumo Medical Corporation
• Owen Mumford Ltd
• MTD Medical Technology and Devices S.p.A.
• ARKRAY, Inc
• Sarstedt AG & Co. KG
• Medline Industries, Inc.

By Type	By Application	By End User	By Region
Safety Lancets Standard Lancets Specialty Lancets	Glucose Testing Haemoglobin Testing Coagulation Testing Other Applications	Hospitals and Clinics Home Care Settings Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Lancets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Lancets Market, By Type:

• Safety Lancets
• Standard Lancets
• Specialty Lancets

• Lancets Market, By Application:

• Glucose Testing
• Haemoglobin Testing
• Coagulation Testing
• Other Applications

• Lancets Market, By End User:

• Hospitals and Clinics
• Home Care Settings
• Others

• Lancets Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE